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Alkaline phosphatase (APase) is a cell surface enzyme found to be
associated with the membrane of lymphoblastic cells and some lymphoid pell
lines. This enzyme appears and disappears in the early differentiation
processes of the cells of the immune system (B and T cells). The appearance
of APase in pre-T cells seems to preceed that of terminal deoxynucleotide
transferase (TdT). The specific role of APase in T cell differention path
way is not known. It has been hypothesized that APase acts as an early
differentiation marker for pre-T cells.
The goal of this research is to produce a monoclonal antibody against
APase using SJL-46 cells, a Pre-T cell line, as the source of the
enzyme. The monoclonal antibody can then be used to- isolate and purify
proteins with APase activity and detect cross-reacting material. At the
cellular level, the monoclonal antibody can also be used to identify APase+
cells, remove APase+ cells and sort APase+ cells from a heterogenous mixture
of cells.
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Partial purification of the. APase from SJL 46 cells by Nonidet P40
solubilization and butanol extraction yielded a 500-800-fold purification.
Mouse myeloma cells SP2/OAgl4, were fused with the spleen cells of
Spraque-Dawley rats immunized with the partially purified APase. Using enzyme-
antigen-immuno-assay method, eight clones producing monoclonal antibodies
against SJL 46 APase were isolated. The objective of the investigation was
met by isolating 8 clones secreting anti-APase monoclonal antibody.
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CHAPTER I
INTRODUCTION
Several immunological techniques have been developed within the last
ten years, most important of which is the production of monoclonal anti
bodies. By fusing normal antibody-forming cells with those of their malig
nant counterparts, Kohler and Milstein (1975) were able to select and clone
the hybrid cell which secreted specific immunoglobulin, known as monoclonal
antibody. Their monumental achievement culminated from discoveries by pre
vious workers. Such discoveries that have helped to broaden the understand
ing of the underlying principles of the production of hybridomas are:
1) the clonal selection theory (Nossal and Lederberg, 1958),
2) the artificial induction of plasmacytomas (Potter and Boyce,
1962), and
3) the development of hybrid selection techniques after fusion
(Littlefield, 1964).
The principle of the monoclonal antibody production technique in
volves the cloning of a single antibody-secreting B-lymphocyte so that
homogenous antibody molecules with identical antigen-binding sites, can be
produced in large quantities. Since B-lymphocytes have limited life spans
in culture, the antibody-producing B-cells from immunized mouse or rat
are fused with myeloma cells. The hybrids, having the ability to make the
desired antibody and the ability to multiply indefinitely in tissue cul
ture, are selected from the heterogenous mixture of hybrid cells resulting
from the fusion of the B-lymphocytes and the myeloma cells. Such hybridomas
are then propagated as individual clones which provide a stable source of
monoclonal antibody.
The application of monoclonal antibody technology immunology,
generally, is enormous. One area where monoclonal antibody makes an
immense contribution is in the functional distinction of T-cell subsets.
In man the identification and characterization of antigens like T4 and
T8 were discovered by using monoclonal antibodies.(Thomas et al, 1982).
Similarly, the specificity .of localization and distribution of the Class I
and Class II major histocompatibility molecules has been improved by the
use of monoclonal antibodies against these molecules (Lemke et al, 1978).
Cell surface markers like, T4, T8, Lytl, Lyt2, and Lyt 3 are
associated with mature T-cells in man and mouse. In T-cell differentiation,
however, certain markers such as terminal deoxynucleotide transferase (TdT)
(Chang, 1971) and FT-1 (Pizmino et al, 1978) have been associated with
pre-T cells. Alkaline phosphatase (APase) is a cell surface enzyme found
on the cell membrane of normal lymphoid tissues and some lymphoma cell lines
(Smith, 1961, 1962; Lagerlof and Kaplan, 1967; Lumb and Doell, 1970). Pre-T
cell lines (SJL-46) and pre-B cell lines (18-81, 18-48) are all rich in
APase (Lumb and Silverstone, in preparation). It has been hypothesized
that APase acts as an early differentiation marker for pre-T cells and its
appearance preceeds that of TdT (Lumb and Silverstone, in preparation).
The goal of this research is to produce monoclonal antibodies against APase
using one of the pre-T cell lines, SJL-46, as the source of the enzyme.
The monoclonal antibody will then be used for the isolation of APase+ cells,
and identification of inactive cross-reacting material.
The specific research objectives are:
1) to grow SJL-46 cells (the source of APase) in mice to obtain
them in large quantities,
2) to partial
i
3) to immuniz lally puxUied
APase, ,
4) to fuse ti g with a mouse
myeloma cd
5) to select
6) to screen bridomas, and




Alkaline phosphatase (APase) represents one of the most widely
studied enzymes. It is found in living organisms from bacteria to
higher plants and animals including humans. Malani and Horecker (1964)
showed this enzyme to be located in the region lying between the pro
toplasmic membrane and the cell wall of Escherichia coli. APase is
also abundant in fishes (Bodansky et al, 1931).
APase has been widely studied in mammalian tissues such as in
testine, placenta, kidney, liver, and bone (McComb, et al, 1979). Using
histochemical techniques, Clark (1961) and Ito (1969) showed that APase
was located on the membrane of the epithelial cells of intestinal micro-
villi.
The study of the localization of APase on the membrane of lympho-
blastic cells, fetal thymus, thymic lymphoma, and other lymphoid tissues
has mainly been based on the results from histochemical and ultrastruc-
tural studies. Smith was the first to/ observe that the normal adult
thymus was negative for APase during a histochemical study (Smith
1961, 1962). Similar studies showed that the enzyme was located on the
fetal thymus cells up to 16 days gestation, on thymic lymphoma cells
and on some cells in normal spleen in areas surrounding the germinal
center (Lagerlof and Kaplan, 1967). Ruuskanan and Kouvalainen (1974)
showed by ultrastructural techniques that APase is localized on the
outer layer of the cell membrane of guinea pig lymphocytes.
Hybridoma Technology
Hybridoma technology was an out growth of the early work on somatic
cell hybridization. Littlefield (1964) developed a method for the selec
tion of somatic cell hybrids using two drug resistant sublines of mouse
cells, one to 8-azaguanine and the other to 5-bromodeoxyuridine. The
former was deficient for the enzyme hypoxanthine guanine phosphoribosyl
transferase (HGPRT) while the latter was deficient for the enzyme thymi-
dine kinase (TK). Mammalian cells have two pathways to synthesize nucleo-
tides for DNA synthesis, the "de novo" pathway, which synthesizes nucleo-
tides from sugars and amino acids and the "salvage" pathway which synthe
sizes nucleotides from preformed hypoxanthine and thymidine. When the
"de novo" pathway was blocked by aminopterin, the only optional pathway
left for the cell in nucleotide synthesis, was the "salvage" pathway,
which was dependent on the presence of the enzymes, HGPRT and TK. The
two drug resistant cell lines, one TK~ and the other HGPRT", were there
fore incapable of surviving in a medium containing hypoxanthine, amino
pterin and thymidine (HAT). The hybrid on the other hand, which contained
TK and HGPRT genes, one from each parent, made both HGPRT and TK
enzymes and hence had the capability to grow in HAT. The gene coding
for the HGPRT was located on the X chromosome and this made the production
of the mutant myeloma cells through single mutation of the X chromosome
in male cells fairly easy.
Cotton and Milstein (1973) showed that when two antibody-producing
cells were fused, four immunoglobulins (Ig) were produced, the two origi
nal molecules, plus two molecules obtained by combining the H chain of
one with the L chain from the other cell. Immunology witnessed a new
era when it was reported that specific antibodies can be manufactured
by means of continuous cultures of antibody secreting fused cells (Kohler
and Milstein, 1975). They fused mouse myeloma cells and spleen cells
from mouse immunized to sheep red blood cells (SRBC). They selected and ex
panded the hybridoma cell line.secreting anti-SRBC antibody. The myeloma
cell line used for this hybridoma also secreted immuuoglobulin (Ig).
Later other myeloma cell lines not secreting Ig were developed. Table 1
shows some of the myeloma tissue culture lines that have been developed
and found useful for hybridoma production.
Fusing Agent
Inactivated Sendai Virus was first used by Harris and Watkins (1965)
to promote fusion. Cotton and Milstein (1973); Kohler and Milstein (1975)
also used Sendai Virus as a fusing agent. Although this technique is
satisfactory, the system tends to be biased towards IgM producing hy
brids (Fazekas de St Groth and Scheidegger, 1980). Davidson and Gerald
(1976) used polyethylene glycol (PEG) to improve induction of mammaline
cell hybridization. The fusion efficiency of PEG was reported to have
improved in the presence of 5% dimethyl sulfoxide (DMSO) (Norwood et al,
1976). Comparing different glycols, Fazekas de St Groth and Scheidegger
(1980) reported that PEG of lower molecular weight was less effective
while PEG of molecular weight 4000 (PEG 4000) was most effective. Many
investigators have recommended concentrations of 30-50% PEG for fusion.
Induction of cell fusion is not limited to Sendai Virus and PEG. Recently
electric field-induced cell to cell fusion was carried out and reported to
be a highly efficient technique (Zimmermann and Yienken, 1982).

















Derived from Ig Secretion Reference
P3.6.2.8.1 +
P3 X63 Ag8
P3X63 Ag8 X BALB/c spleen -
P3X63 Ag8
210 Lou plasmacytoma rat -
U-266 +
82266AR
Kohler and Milstein, 1975
Kohler and Milstein, 1976
Shulman et al, 1978
Kearney et al, 1979
Galfre et al, 1979
Olson and Kaplan, 1980
Pickering and Gelder, 1982
All myeloma cell lines listed are HGPRT"
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Ig = Immunoglobulin
+ = Produce and secrete Ig
= Neither produce nor secrete Ig
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Screening Assays
The choice,of an appropriate screening assay is one of the most vital
aspects of hybridoma production. Basically, any method which enables one
to detect the desired antibody with specificity and efficiency may be used.
The guiding principles in the selection of a particular screening assay
are reliability, speed, cost, and reduction.of labor. Unless the assay
can be performed with specificity, in a reasonable time, at low cost,
and little effort, the production of hybridomas is likely to fail. Catt
and Tregear (1967) developed the solid-phase radioimmunoassay technique
and the method was later used to identify monoclonal antibodies. The
assay is based on the fact that polyvinyl surfaces tightly adsorb most pro
teins. Soluble protein antigen was first attached to the tube, then its
corresponding immunoglobulin (Ig) was added. This resulted in antigen-
antibody reaction. To reveal this reaction 125I-labelled anti-immunoglobulin
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or I-labelled staphylococcal protein A, which binds specifically with the
Ig, was added (Coding, 1978). Specific antigen-antibody reaction was re
vealed by positive count using a scintillation counter. This method was
later adapted to detect monoclonal antibodies to viral antigens (Oi et al,
1978); Nowinski et al, 1979).
Engvall and Pesce (1978) and Voller et al (1979) adapted the solid-
phase radio-immunoassay to enzyme-linked immunosorbent assay (ELISA) to
detect monoclonal antibodies. Here the anti-immunoglobulin or protein A
was conjugated to an enzyme such as peroxidase, alkaline phosphatase or
g-galactosidase. Addition of the corresponding enzyme substrate revealed
the specificity.of the antigen-antibody reaction. The avoidance of isotopes
and the visual reading provided by this method are some of the advantages of
ELISA over the solid-phase radioimmunoassay.
Using the catalytic activity of placental alkaline phosphatase,
Jemmerson and Fishman (1982) developed.a convenient assay for the detec
tion monoclonal antibodies which bind the enzyme by reversing the reagents
of the ELISA test. Goat anti-mouse IgG was first attached to the solid-
phase. Culture fluid from anti-APase secreting hybridomas was then
added. This was followed by the addition of alkaline phosphatase. The
specificity of the monoclonal antibody to the enzyme, was revealed by
using p-nitrophenyl phosphate as the substrate for the enzyme. The sensi
tivity of the assay was 10 ng antibody per milliliter and the assay was
applicable to detection of monoclonal antibodies of other isozymes of
alkaline phosphatase (Jemmerson and Fishman, 1982).
Monoclonal Antibodies Raised Against Enzymes
Monoclonal antibodies have been produced to several enzymes. The
majority of the antibodies was raised by the mouse-mouse hybridoma method
(Kohlerand Milstein, 1975), while in few cases rat-rat hybridoma (choo
et al, 1980) or rat-mouse hybridoma (Levy et al, 1981) methods were used.
In each of these hybridomas the enzymes were either from different species
of animals or were polymorphic enzymes. In this hybridoma the SJL 46 cell
line which is the source of the APase (antigen) is a mouse cell line.
Mice will not be used for immunization because the enzyme is not poly
morphic and, therefore, it is not likely to stimulate an adequate immune
response in mice. A different species of animal, Spraque-Dawley rat, is
a better choice of animal for immunization. Spleen cells from such immune
rat will be fused with SP2/0 Ag 14 myeloma cell line (Shulman et al, 1978)
to obtain the enzyme-specific hybridomas. The hybridoma cell line, which
is foreign to both the rat and the normal mouse must be grown in serum-free
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culture medium or in nude mice for the production of monoclonal antibodies.
Highly purified enzymes have been used as antigen in some cases, while
in others, enzyme-specific monoclonal antibodies were still obtained
by using partially purified enzymes. Fambrough et al (1982) and Choo
et al (1980) obtained enzyme-specific hybridomas by using highly purified
human acetylcholinesterase and monkey phenylalanine hydroxylase as anti
gens respectively. Kramer et al (1980) and Siddle et al (1981) on the
other hand obtained enzyme-specific hybridomas by using only partially
purified RNA polymerase II and 5 -nucleotidase as antigens. Also,
Arklie et al (1981) and Wray and Harris, (1982) used partially purified
human alkaline phosphatase, as the immunogen for the hybridoma production.
CHAPTER III
MATERIALS AND METHODS
Preparation of Lymphoid Cell Line SJL 46
The source of the antigen (APase) was the SJL 46 lymphoma cell line
which was obtained from Dr. Ed Siden, University of Florida, Gainsville,
Florida. The cells were first cultured in RPM1 1640 medium (Appendix A)
and incubated at 37°C with a constant supply of 5% C0_. Large quantities
of SJL 46 cells were obtained by injecting 300 mice intraperitoneally with
10 cells per mouse in 0.5 ml of RPM1 1640 medium. Six days after injec
tion, each mouse was killed by cervical dislocation and disinfected with
70% alcohol. The abdominal skin was removed, leaving the peritoneum. Ten
milliliters of 0.1 M Tris buffer containing 0.15 M NaCl was then injected
into the peritoneal cavity with a 18 gauge, 1 1/2-inch needle. After
gently massaging the abdomen, the fluid was withdrawn. The cells were
collected into 50 ml centrifuge tubes and washed thrice with 0.1 M Tris
buffer containing 0.15 M NaCl. The cells were counted in a hemocytometer,
pooled and frozen at -20°C deep freezer ready for enzyme purification.
Alkaline Phosphatase Assay
The volume of the reaction mixture was 0.5 ml and consisted of 0.8 M
diethanolamine (DEA) at pH 10.38 mM p-nitrophenyl phosphate (pNPP), and
the enzyme extract (Njoku, et al, 1982). Dephosphorylation of the sub
strate, pNPP catalyzed by the APase released p-nitrophenol (PNP). The
absorption of the released PNP was read at a wavelength of 400 nm in
Zeiss PMQII Spectrophotometer. The spectrophotometer was interfaced to a
Hewlett-Packard 9825 computer which calculated the change in product per
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unit time. Enzyme activity is expressed as the amount of PNP in ymole,
liberated per milliliter per minute in the presence of 1.0 M DEA pH 10.0.
The specific activity was calculated by dividing the enzyme activity by
the protein concentration.
Measurement of Protein Concentration
Protein concentration was determined by the Bradford method (Bradford,
1976). The method is based on the fact that Coomassie blue dye when re
acted with protein, forms protein-dye complex which has an absorbance of
595 nm. The absorbance, which is directly proportional to the concentration
of the protein, was measured using the Nissei Hitachi Model 1023 spectro-
photometer. A standard curve of absorbance versus concentration of bovine
serum albumin (BSA) was constructed and the concentration of the unknown
protein was determined by interpolation.
Alkaline Phosphatase Purification
Purification Scheme. The primary aim was to purify the enzyme at least
300-500 times. At this level of purification the enzyme would then be used
as an immunogen containing 200 mg protein per dose. The flow chart of the
purification scheme is shown in Figure 1.
The membrane fraction was pelleted, solubilized with a detergent, NP40,
and extracted with cold butanol.
Pelleting of the SJL 46 cell Membranes. The cell suspension (crude
sample) was first thawed on ice and vortexed. At this stage all the cells
were lyzed. The APase activity and the protein concentration of the crude
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residue (1st Pellet) and the supernatant (1st Sup) were then estimated
for enzyme activity and protein concentration.
Solubilization with NP40. The 1st Pellet was solubilized in 1% NP40,
incubated at 45°C for 30 minutes and centrifuged at 190,000 * g 1 hour.
The residue (1st NP40 Pellet) and the..supernatant (1st NP40 Sup) were
estimated for APase activity and protein concentration. The procedure
was repeated twice to obtain 2nd NP40 pellet, 2nd NP40 Sup, 3rd NP40 pellet,
and 3rd NP40 Sup. The three NP40 supernatant samples were stored frozen
for extraction in butanol.
Butanol extraction. Each NP40 supernatant was extracted in the cold
with 30% butanol. The sample was placed in a vial which was in turn placed
in an insulated metal container. The whole assembly was placed on a cold
Plate, for which the temperature was adjusted to about 3-4°C. The butanol
was brought to 4°C before use. The butanol was gradually added to the NP40
supernatant with continuous stirring until the required concentration was
reached. The samples were left stirring for 30 minutes after which they
were centrifuged at 190,000 x g for 1 hour at 4°C. The clear aqueous layer
which contained the enzyme was removed. The enzyme activity and protein
concentration of the extracts were estimated. The extracts were accordingly
referred to as ButSup-1, ButSup-2, and ButSup-3, respectively.
Removal,of butanol by dialysis. The enzyme used for immunization was
the ButSuP-2 from Crude Samples II and III. The butanol was removed by
dialysis before the APase was injected in Spraque-Dawley rats. The dialysis
bag was soaked in distilled water overnight.. The ButSup-2 was placed in the
bag and both ends were tied. The samples were dialyzed in 6.1 M Tris buffer
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containing 0.15 NaCl, for 10 hours with continuous stirring in the cold.
The enzyme activity and the protein concentration of the samples were
determined after dialysis.
Electrdphdresis
Discontinuous sodium dodecyl sulfate polyacrylamide gel electro
phoresis (SDS PAGE) was performed on the partially purified APase. The
electrophoresis was done in a slab gel using the Laemmli gradient gel
electrophoresis method (Laemmli, 1970). The components of the gels are in
Appendix B. The gradient gel was mixed using the gradient mixer. The
stacking gel was layered on the gradient gel and allowed to set. Electro
phoresis was run in 1.0 M Tris HC1 at pH 8.8.
The APase sample containing 30 yg protein, enzyme activity of 311
nmoles PNP liberated per ml per minute, and the tracking dye in 25 yl
were placed in 6 wells. An additional well contained standard membrane
glyco proteins. Electrophoresis was run at 20 mA per gel for 6 hours.
The gel was stained with silver stain to indicate the protein bands.
The components of the silver stain are in Appendix C. The gel was fixed
in solution I for 30 minutes, in solution II for 10 minutes, and in solu
tion III for 30 minutes. It was then rinsed in deionized water for 30
seconds and transferred into solutions IV and V for 30 minutes each. The
gel was then rinsed in deionized water for 30 seconds and developed in
solution VI for about 10 minutes. Finally it was destained in solutions
VII and VIII for 5 minutes and 45 seconds respectively.
The APase band was identified by staining the gel with the APase
stain. The stain contained 25 mg Fast blue RR and 25 mg naphthyl phos
phate ASMX dissolved in 25 ml 0.2 M Tris HC1 PH 9.0. The gel was stained
in the dark at 4°C for about 2 hours.
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Immunization of Sprague-Dawley Rats
Four Sprague-Dawley rats were obtained from the Center for
Laboratory Animal Resources, Atlanta University Center. The partially
purified APase was emulisified in Complete Friend's Adjuvant (CFA) at
the ratio of 2 parts APase to 1 part CFA. The rats were bled prior
to injection. Each rat was injected intraperitoneally with 1.0 ml of
the APase-CFA emulsion containing 200 yg protein. Two additional
injections of the same dosage were given to each rat at two week
intervals in CFA. The rats were bled prior to each injection.
The antibody titer of the pre-injection, and post-injection sera samples
were determined by the enzyme antigen immunoassay (EAIA) (Jemmerson and
Fishman, 1982). A booster injection was given three days before fusion.
The booster dose was given intravenously with 0.1 ml APase containing
10 yg protein per ml and at the same time intraperitoneally with 0.5 ml
APase containing 10 yg per ml. Since this was determined to be inadequate,
subsequent booster injections were given at 50 yg/ml intravenously and
intraperitoneally.
Standardization of the Screening Assay
To ensure that the EAIA method would work, the test was standardized us
ing dog anti-goat IgG as the secondary antibody, goat anti-Escherichia coli
APase as the primary antibody, E. coli APase as the antigen, and pNPP as
the enzyme substrate. The secondary antibody was diluted to 10 yg/ml in
0.1 M Na2C03 PH 9.0 and was plated into microtiter wells at 100 yl per
well. The plate was incubated at 4°C overnight. The wells were washed
twice with 25 mM Tris HC1 pH 7.5 containing 0.1% Tween 20 and 2 mM MgCl2
(wash buffer). Each well was blocked with 200 yl of 25 mM Tris HC1 pH 7.5
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containing 5% FCS and 2 mM MgCl2 (working buffer) for 4 hours at 4°C.
The wells were then washed twice. Two fold serial dilutions of the
primary antibody beginning with 1:20 dilution, were performed in the
working buffer. Two hundred yl of each dilution was added to the
corresponding well and the test was incubated at 4°C for 4 hours. The
wells were washed twice. One hundred yl of E.coli APase with enzyme
activity of 50 nmoles PNP liberated per ml per minute was added to each
well and incubated at 4°C for 4 hours. One hundred yl of 33.8 mM pNPP
prepared in 1.0 M DEA pH 8.6 was added to each well and incubated at
37 C for 1 hour. Normal goat serum was used as the negative control
while the working buffer was used as the buffer control.
The test was repeated with the following variations:
1) the test was incubated at room temperature for 1 hour instead
of at 4°C for 4 hours,
2) enzyme activities of 20 nmoles/ml/minute and 30 nmoles/ml/
minute were used instead of 50 nmoles/ml/minute.
Table 2 shows the results of the EAIA experiments. With enzyme
activity of 50 nmoles/ml/minute and other factors constant, non
specific positive reactions were obtained (Experiment I). With
enzyme activity of 30 nmoles/ml/minute and other factors constant speci
fic reactions were obtained (Experiment II). Further decrease of enzyme
activity to 20 nmoles/ml/minute gave the same result as Experiment II
except the time for color development was much longer (iJg - 2 hours after
substrate addition). Incubation temperature of 4°C for 4 hours and room
temperature for 1 hour gave the same result as Experiment II.
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Table 2. Enzyme—antigen—immunoassay
± Primary EAIA Reaction
Experiment Antibody Dilution 20 40 80 160 320 640 1280
I Anti-jE. coli APase +2
Goat serum
Buffer control
II Anti-E. coli APase
Goat serum
Buffer control
Experiment I included 50 nmoles PNP/ml/minute of E. coli alkaline phosphatase
activity. " ~"
Experiment II included 30 nmoles PNP/ml/minute and 20 nmoles PNP/ml/minute
°f E' £°i* alkaline phosphatase activity.
19
The following conclusions were drawn:
1) for hybridoma screening assays, the EAIA steps should be in
cubated at room temperature for 1 hour, but incubation after
substrate addition should be at 37°C for 1 hour,
2) the standard activity of the APase in the test should be 30
nmoles/ml/minute,
3) the concentrations of the secondary antibody and the buffers
should be as recommended by Jemmerson and Fishman, 1982.
Determination of Antibody liters of Rat Sera
The experiment was carried out as described above. The secondary
antibody was the goat anti-IgG, purchased from Flow Laboratories. The
secondary antibody concentration, the buffers used and their concentra
tions were as described in the standardization procedure above. The
incubation steps were carried out at room temperature for 1 hour and
after substrate addition the incubation was at 37°C for 1 hour. The
substrate was prepared in 1.0 M DEA pH 10 instead of in 1.0 M DEA pH 8.6
used for IS. coli APase above. The APase activity used was 30 nmole PNP/
ml/minute.
Preparation of Mouse Myeloma Cells
Figure 2 shows the flow-chart of the processes of cell fusion and
cloning. The SP2/0 cells were obtained from Dr. Alison Mawle, Immunology
Laboratory, Center for Disease Control, Atlanta, Georgia. The cells were sub-
cultured in Diilbecco's Modified Eagles Medium (DMEM) (APPendix D) with 10% Calf
serum. Incubation was at 37°C in 6% C02. Subculturing of the cells was done
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growth area (T-?25 flask) to 75 cm growth area . (T-75 flask) and grown
for 4 days. Twenty four hours before fusion, the cells were split 1:1
in fresh medium. On the day .of fusion, each flask was shaken gently
to dislodge the cells from the flask wall. The cell suspension was
then centrifuged at 700 x g for 5 minutes. The supernatant was filtered
and stored frozen to be used as conditioned medium for cloning. The
pellet was resuspended in 50 ml serum-free DMEM and centrifuged at 700 x g
for 5 minutes. The centrifugation was repeated twice and the pellet was
finally suspended in 5.0 ml serum-free DMEM. The cells were then counted
in a hemocytometer.
Preparation of Spleen Cells for Fusion
The rat, which was boosted 3 days before, was anesthesized with ether,
then slaughtered at the neck to collect blood. The animal was wiped with
70% alcohol and then placed face up under the hood and a cut was made
through the skin with scissors just below the ribs. The skin was separated
along the incision and pulled firmly towards the head and tail to expose
the peritoneum. The peritoneum was disinfected with 70% alcohol and the
spleen was removed with sterile scissors and forceps into a sterile petri
dish containing 10.0 ml serum-free DMEM. With two sterile, bent, 21 gauge
needles, the spleen cells were teased into the medium. The medium was
withdrawn and expelled several times with the pipette to separate compact
cells and get them into suspension. The cell suspension was transferred
into a sterile 12.0 ml centrifuge.tube and left for 2-3 minutes. While
the large particles settled at the bottom of the centrifuge tube, the
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cell suspension was transferred to a 50 ml centrifuge tube that was
filled.to 50 ml mark with serum-free DMEM. The cells were pelleted by
centrifugation at 700 x g for 5 minutes. The process was repeated twice
and the final pellet was suspended in 10.0 ml serum-free DMEN. The cells
were then counted in a hemocytometer.
Preparation of Polyethylene
Polyethylene glycol molecular weight 4,000 was weighed into a clean
screw cap bottle. The bottle and the PEG were then autoclaved for 20
minutes. The autoclaved polyethylene glycol (PEG) was allowed to cool
and then added to the DMEM containing 5% DMSO. The final concentration
of PEG was 50% (w/v). The solution was dispensed in 1.0 ml alliquots and
stored frozen at -20°C until used.
Hybridization of SP2/0 and Rat Spleen Cells
The SP2/0 and the spleen cells were first mixed in a 50 ml centrifuge
tube in the ratio of 1:4 (2.4 X 107 SP2/0 cells to 9.8 X 107 spleen cells).
The mixed cells were pelleted at 700 x g for 5 minutes. The pellet was broken
up by tapping the bottom of the tube. The 50% PEG was gradually added to
the pellet. One ml PEG was added to 1 X 108 cells. The mixture was left
for 45 seconds with continous shaking. Ten ml of serum-free DMEM was added
to the mixture over a period of 3 minutes, shaking the tube continuously.
The volume was then brought to 50 ml with serum-free DMEM. The cells were
centrifuged at 700 x g for 5 minutes to remove the PEG. The supernatant
was decanted. Mouse spleen cells (1.2 X 108 cells in 4 ml DMEM) were added
to the tube as feeder cells. The suspension was divided evenly into two
tubes and centrifuged. Cells in one tube were.resuspended in DMEM-HAT
medium (Appendix F) with 10% FCS to contain 1 X 106 cells per ml. The
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cell suspension was distributed into 96-well microtiter plates at 200 yl
per well. Cells in the other tube were resuspended in DMEM medium with
10% FCS to contain 1 X 10 cells per ml.. The suspension was similarly
distributed into 5 microtiter plates at 200 yl per well. Twenty four
hours later the DMEM medium was changed to DMEM-HAT medium. All the
plates were incubated at 37°C in 6% C0? for at least 10 days.
Screening of Culture Supernatants
After 14 days of incubation at 37°C, the culture supernatants of the
fused cells were screened for anti-APase antibody production. The positive
wells were cloned while the negative wells were kept and rescreened at 21
days. The screening assay method was the EAIA described earlier. In this
case the tissue culture supernatants were not diluted serially. The con
trols used with the test were:
1) a positive control containing the polyclonal antibody from the
immunized rat,
2) a negative control containing the SP2/0 myeloma supernatant
fluid, and
3) a buffer control containing the 25 mM Tris buffer containing
5% CFS and 2 mM MgCl2<
Preparation of Medium for Cloning
The supernatant fluid of SP2/O myeloma cells fed for 24 hours, was
used as the conditioned medium (Appendix F). The tissue culture super
natant was transferred into 50 ml centrifuge tubes and spun at 208 x g for
15 minutes to remove dead cells. The fluid was filtered through a 22
micron membrane filter. Its sterility was checked by incubation at 37°C
for 24 hours. It was then stored frozen at -20°C. For use, the conditioned
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medium was thawed and mixed with equal volume of fresh feeding medium
(DMEM). Ten percent calf serum, 50 I.U. penicillin/50 jig streptomycin, and
0.3 mg glutamine were added to replace the spent additives in the conditioned
medium.
Preparation of Macfdphage Feeder Cells
Three mice were injected intraperitoneally with 0.3 ml CFA 4 days
before cloning. Twenty four hours before cloning, each mouse was killed
by cervical dislocation and disinfected with 70% alcohol. A cut was made
through the skin just below the ribs. The.skin was separated along the
incision and pulled firmly towards the head and tail to expose the peri
toneum. With 18 gauge needle 10.0 ml of DMEM was injected into the peri
toneal cavity of each mouse. After gently massaging the abdomen, the
ascites fluid was collected in a sterile 50.0 ml centrifuge tube. The
macrophages were counted in a hemocytometer. They were then plated into
microtiter plates at 100 yl containing 1 X 104 cells per well. The plates
were incubated overnight at 37°C.
Cloning of Hybrids
Wells giving strong positive EAIA test were selected for cloning.
With a sterile pipette, the medium of the well was with drawn and ex
pelled several times to dislodge the cells. The cells were resuspended
in 1.0 ml of DMEM and counted in a hemocytometer. The cells were diluted
to give 80 cells per ml in a 20 ml amount. A doubling dilution was made in
5 tubes with a total volume of 10.0 ml per tube. The final cell concentra
tions were:
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8 cells per well,
4 cells per well,
2 cells per well,
1 cell per well, and
0.5 cell per well.
Each dilution was plated into 96 wells of a microtiter plate, containing
the mouse peritoneal macrophage feeder layers at 100 ml per well. Each
well was observed with inverted microscope as from the 7th day for the
appearance of single ball of cells which later form clusters of cells.
After satisfactory cell growth, each monoclonal well was again screened




Preparation of Lymphoid Cell Line SJL 46
To obtain enough APase for purification, the SJL-46 cells were grown
in mice. From the 2.38 X 10 SJL-46 cells injected into mice 6.19 X 1010
cells were recovered after 6 days.
Alkaline Phosphatase Purification
The cells were split into Samples I and II. Each sample was solu-
bilized with NP4O and extracted with butanol. Tables 3 and 4 show
the results of these treatments. In each experiment the butanol extract
of the 2nd NP40 Sup gave the best results. The fold purification was
524 and 838 for the two experiments with 41% and 69% overall yield re
spectively. Thus, the level of purity of the two samples met the ex
pected objective of 300-500, and the percent yield was good. •
Electrophoresis
The partially purified APase was electrophoresed. Figure 3 shows
the result of the electrophoresis. The protein bands were stained yellow
with silver stain. The corresponding APase band was identified
by the APase stain which stained blue. From the standard protein bands,
the molecular weight of the APase was 135,000.+. 8,000 (Figure 4).
Immunization of Sprague-Dawley Rats
Table 5 shows the anti-APase titer of pre-injection and post-injec
tion sera. After two weeks of injection, the anti-APase antibody titer
increased 8-fold, and after four weeks it was increased in all four rats
64-fold.

































































































Total APase activity is expressed in ymole PNP liberated/minute
2
Specific activity is expressed in ymole PNP liberated/mg protein/minute
NJ
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Titer is the inverse of the last dilution which gave a positive
result
Positive control was E.coli APase and Goat anti E.coli APase
cNegative control was SJL 46 APase and normal rat serum
Buffer control was working buffer without APase
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Screening of Culture Supernatant
After 14 days of incubation of the plates, clusters of large cells
started to appear in many wells while the tiny spleen cells disappeared
from almost all the wells. All the 960 wells plated were screened by
EAIA method. Eight wells were positive by showing strong yellow color
after 1 hour incubation of the test at 37°C. Figure 5 shows an example
of one EAIA plate with 4 positive wells.
Cloning of Hybrids
Six of the eight positive wells were cloned. The positive clones
obtained from the six wells are shown in Tables 9 and 10.
Eight positive clones from cells suspended in DMEM-HAT immediately
after fusion were obtained. These clones appeared earlier
Five positive wells obtained from hybrids, suspended in DMEM after fusion
and 24 hours later changed to DMEM-HAT became negative after the first
cloning (Table 7).
Estimation of Fusion Frequency
Figure 5 shows the estimation of the fusion frequency of the hybri-
doma. The overall fusion frequency was 1 in 2.8 X 107.
•sr
33
Table 6. Cloning results of the positive well from DMEM-HAT
Positive well Number of cells Number of positive wells
after fusion plated per well obtained from each plate
1A 0.5
Table 7. Cloning results of the positive wells from DMEM to DMEM-HAT
Positive wells Cell count per ml Number of cells plated Positive wells after
after fusion per well cloning
IB 7.5 X 104 8,4,2,1,0.5 0
2B 4.5 X 104 8,4,2,1,0.5 0
3B 4.5 X 104 8,4,2,1,0.5 0
4B 5.0 X 104 8,4,2,1,0.5 . 0
5B 1.9 X 105 8,4,2,1,0.5 0
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Fusion frequency 1 in 4.9 X 107 1 in 7.0 X 106
Overall fusion
frequency 1 in 2.8 X 10
CHAPTER V
DISCUSSION
This investigation proposed to produce monoclonal antibody against alka
line phosphatase (APase) isolated from a lymphoid cell line, SJL 46. A high
degree of purification was achieved by solubilizing the enzyme with NP40
detergent and extracting it with butanol. Purification on the order of 20-30
fold was achieved by Davis (1977) who used this method to purify APase from
mouse placenta tissue. The improved purification achieved with Samples I
and II could be due to a better recovery of APase from pellets. Unlike the
procedures of Davis in which the supernatants were pooled before butanol ex
traction, the individual NP40 supernatants were extracted separately with
butanol. While Davis obtained a purification fold of 16.6 after butanol ex
traction of the pooled NP40 supernatant a much higher purification fold of
838 was obtained in this investigation when the individual NP40 supernatants
were extracted separately with butanol. The higher fold purification
achieved could be due to the fact that the APase was purified from a homo
geneous cell line instead of from tissue which contained more extraneous materials.
Electrophoresis of the partially purified APase shows three protein bands
including that of the APase. The proteins used as standards are the red cell
membrane proteins (Fairbanks et al, 1971) instead of the commercially available
standard proteins. This is because the APase is also a membrane protein.
The molecular weight of the partially purified APase was 135,000 + 8000.
Davis (1977) obtained the molecular weight of 170,000 for placental alkaline
phosphatase. The differnece could be due to the fact that Davis purified the
APase from a tissue while this investigation purified the APase from a cell line.
Our immunization protocol gave a very satisfactory immune response in rats.
Although 2-4 volumes of complete adjuvant to 1 volume of antigen has been
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suggested to give a very good immune response (Hum and Chantler, 1980)
our investigation demonstrated that 1 volume of complete Friend's
adjuvant to 2 volumes of APase could still give an equally adequate
immune response.
The proportion of the myeloma cells to the spleen cells (1:4) used in
the fusion yielded satisfactory results: This agrees with the suggestion
that higher proportion of the spleen cells to myeloma cells should be
used to increase the chance of myeloma-spleen cell fusion and decrease
that of myeloma-myeloma cell fusion (Kohler and Milstein, 1975, 1976).
The fusion frequency of the hybridoma is very low. This agrees
with Stahli et al (1980) who said that soluble antigens induce low fusion
frequencies. In general, low fusion frequency is due to a low number of
specific B cells in the heterogenous mixture of spleen cell population
at the time of fusion. The specific B cell population could be increased
by giving 3-4 booster dose injections piror to fusion (Stahli et al, 1980)
or by culturing the immune spleen cells in vitro in the presence of the
antigen, for 4 days, prior to fusion (Fox et al, 1981).
One of the most striking features in the cloning of hybrids in this
investigation, was that out of the six strongly positive fusion wells
cloned, only one yielded 8 positive clones, while the rest gave negative
clones after the first cloning. Also, it was observed that the positive clones
appeared earlier and came from the hybrids suspended directly in DMEM-HAT
medium, while the unstable clones appeared later and came from hybrids sus
pended in DMEM but changed to DMEM-HAT after 24 hours. While the issue of
frequent loss of chromosomes by hybrid cells, generally, could be attribu
ted to the instability of the positive clones, the observation by Fazekas
de St Groth and Scheidegger-(1980) that SP2/0-hybrids were more prone to
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chromosome loss than the X63-hybrids could be more applicable here. They
explained that many clones positive for antibody production in the first
incorporation test (usually between day 14 and 21) registered later as
non producers. Interspecies hybridization is another contributive factor
to chromosome loss. Most interspecies hybrids are unstable, and it is not
surprising if this is the case. The enhancement of positive clones by
direct suspension of hybrids in DMEM-HAT in the experiment agrees with
Fazekas de St Groth and Scheidegger (1980), when they observed that clones
of hybrid cells resuspended directly in HAT medium appeared earlier and had
a higher frequency of survival than those suspended directly in the growth
medium and changed to HAT after 24 hours.
The screening assay employed in the experiment was the enzyme-antigen-
immunoassay (EAIA) by Jemmerson and Fishman (1982). It specific and re
liable, if the test is properly standardized for the desired experiment
before being employed. The positive and negative controls gave their
expected results throughout the experiments and reproducible results were
obtained. This agrees with the observation of Jemmerson and Fishman (1982)
that EAIA technique could be applicable to the detection of antibodies to
isozymes of human placental APase.
Finally, the objective of the investigation to produce monoclonal
antibody against SJL46-APase was accomplished by obtaining eight clones
secreting anti-APase monoclonal antibody.
To fully utilize the anti-APase monoclonal antibody in the study of
T cell differentiation pathway the following additional work on the mono
clonal antibody is recommended:
1) to perform Ouchterlony test on the antibody using anti-rat IgM,
IgGl-4, IgA to determine its isotype,
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2) to perform EAIA test using the neuramimidase-treated APase antigen
to determine whether the monoclonal antibody binds to the
sugar moiety or the protein moeity of the APase,
3) to perform Western blot of the APase to further confirm its
specificity, and
4) to perform Ouchterlony test on the monoclonal antibody using
extracts from other APase lymphoid cell lines, human placenta,
E. coli, calf intestine, beef liver, mouse placenta, and SJL 46
antigens so as to determine the immunological relationship
between the SJL 46 APase and these isozymes.
In spite of the success of this investigation, there are problems
unsolved in the hybridoma technology. The specific role of the macrophage
feeder cessl is still not quite understood. The issue of chromosome loss
by hybrid cells can still not be completely remedied.
While the problems remain, a lot can be achieved in APase-hybridoma
technology of certain factors are kept in mind. Before starting APase-
hybridoma, every step must be clearly understood. It is necessary to
partially purify the enzyme to enhance its specific immune response.
It is very important to decide on the screening assay and to standardize
it to the desired specificity before starting the hybridoma experiments.
Contamination of culture cells is a major problem in hybridoma technology,




1. Five hundred to eight hundred fold of APase purification was
obtained from SJL- 46 cells by solubilization with NP40 detergent
and extracted with butanol.
2. One part of complete adjuvant to two parts .of the partially puri
fied SJL 46 APase gave adequate immune response in rats for hybri
dization.
3. Mouse myeloma cells (SP2/0) and spleen cells from a rat immunized with the
APase were fused in the ratio of 1:4.
4. The anti-APase monoclonal antibody was detected by enzyme—antigen-
immunoassay (EAIA), a reversed ELISA technique, using the catalytic
activity of the SJL 46 APase.
5. Eight clones secreting anti-APase monoclonal antibody were isolated.
6. Clones from cultures resuspended immediately after fusion in DMEM-HAT
appeared earlier and had a higher number of surviving hybrids than
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RPMI 1640 (Gibco Laboratories) 98.0 ml
Fetal Calf Serum 10.0 ml
2-Mercaptoethanol (5 X 10~3 M) 0.01 ml
Penicell/Streptomycia (5000 I.U./ml, 5000 mcg/ml) 1.0 ml
Glutamine (29.2 mg/ml) (Gibco Laboratories) 1.0 ml
Filter sterilize and incubate at 37°C for 24 hours to check
sterility. Store in the refrigerator.
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APPENDIX B
Components of SDS PAGE
1. Stacking gel
4.5% Acrylamide
1.2% N,N -methylene bis acrylamide
0.077% Sodium dodecyl sulfate
2. Gradient gel (5-15% (16.0 ml)
Low (5%) Components High (15%)
2.83 ml 30% Acrylamide 8.5 ml
1.7 ml 1.0 M Tris Hcl pH 8.8 1.7 ml
12.47 ml Deionized water 6.88 ml
17.0 yl 100% N,N,N1,N1-tetramethylene 17.0 yl
diaminine












Components of Silver Stain
Components
45% Methanol, 12% Acetic acid
10% Ethanol, 5% Acetic acid
10% Glutaraldehyde
10 yg/ml Dithiothreitol (DTT)
0.012 M AgN03
0.28 M Na2CO3 with formalin (3 drops)
1% Acetic acid
Farmer's reducer for reduction of surface stains
Solution A = 7.5% Potassium ferricyanide
Solution B = 24% Sodiumthiosulfate
Working solution: 2.5 ml A + 10 ml B + 250 ml
deionized water.
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Dulbecco's Modified Eagle's Medium (DMEM)
Reinforced Minimal Essential Medium ■ ^16 ml
1M HEPES(N-2-Hydroxyethyl piperazine-N2-ethan-sulfonic acid 12.0 ml
Glutamine (100 X)(Gibco Laboratories) 12.01 ml
Insulin-transferrin-selinium (ITS) 24.01 ml
Sodium bicarbonate (7.5%) 12.0 ml
5 X 10 M 2-Mercaptoethanol 12.o ml
Nonessential amino acids (100 X) 12.0 ml
Fetal calf serum 100 mi
Filter sterilize; incubate at 37°C for 24 hours to check
sterility. Store in refrigerator.
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APPENDIX E
Preparation of DNEM-HAT Medium
DMEM (Appendix C) 49.0 ml
HAT (Hypoxanthine, Aminopterin, Thymidine)-media
supplement (50 X) 1.0 ml
Store frozen




SP2/0 Culture supernatant 100.0 ml




Conditioned medium (thawed at 37oC water bath) 50 ml
Glutamine (29.2 mg/ml) (Gibco) 0.5 ml
Calf serum 5.0 ml
DMEM (Appendix D) 50 ml
